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Feed intolerance is a common problem in the neonatal intensive care unit (NICU), more so with preterm infants. It is a major factor affecting duration of hospitalization, 
results in caloric deprivation and growth restriction requiring 
prolonged parenteral nutrition and, hence, associated with adverse 
effects of the same [1].
The etiology of feed intolerance can be (1) physiological - common 
with prematurity and (2) pathological - associated with sepsis, 
necrotizing enterocolitis (NEC), idiopathic, surgical, babies on 
invasive ventilation, and asphyxia. Factors causing feed intolerance 
in premature infants are immature intestinal motility, digestive 
enzymes immaturity, consequence of ineffective, infrequent, and 
uncoordinated bowel activity. This is attributable to the absence 
of migratory motor complex (MMC), resulting in delayed gastric 
emptying, and prolonged gastrointestinal transit time. Functional 
immaturity is also a predominant cause.
The drugs used commonly to establish the full enteral 
feeds quickly in NICU are metoclopramide and domperidone. 
Erythromycin is a potent analog of the gastrointestinal 
hormone motilin. It promotes gastric emptying and induces 
intense bursts of Phase III MMC contractile activity in 
proximal intestine, which are thought to be responsible for the 
transit of luminal contents through the gut [2-5]. The use of 
erythromycin as a prokinetic agent has become fairly common 
in NICUs.
There are studies [6], which conclude, that erythromycin 
is effective only in >32 weeks and some studies [7-9] have 
concluded that erythromycin acts as a prokinetic agent in babies 
with gestation both <32 weeks and >32 weeks in a dose-dependent 
manner. Studies have used drugs at different doses - high dose 
(40 mg/kg/day) and the low dose at 3–12 mg/kg/day [10-12] 
and both as a prophylactic [13-15] and rescue [10-12] and by 
different routes and have concluded differently. Erythromycin has 
been also shown to be useful in conditions other than functional 
immaturity [2,16-20] and in term neonates with feed intolerance. 
Erythromycin has been used currently in pediatric and in adult 
age group as an antibiotic. We wish to study the different doses of 
erythromycin as a prokinetic in both term and preterm neonates 
and safety of erythromycin as a prokinetic agent in babies with 
feed intolerance.
ABSTRACT
Objective: The objective of this study was to compare the effect of high and low dose of erythromycin with placebo and to 
determine the efficacy and safety of oral erythromycin for feed intolerance in neonates admitted to the neonatal intensive care 
unit. Methodology: The study was a double-blind, randomized, and placebo-controlled trial. Term and preterm babies having 
feed intolerance were included in the study, and babies with congenital malformations, necrotizing enterocolitis, and sepsis 
were excluded from the study. After parental consent, the subjects were randomized into Groups 1, 2, or 3 to receive low-dose 
(3 mg/kg/dose) or high-dose (10 mg/kg/dose) oral erythromycin estolate or the placebo (equal volume of 5% dextrose). Feeding of 
all the study neonates was managed as per the unit protocol and babies were monitored for the complications. The primary outcome 
was the time to reach full feeds of 150 ml/kg/day, without significant gastric residuals. Results: Of 58 eligible babies, 84.5% were 
preterm babies. The median time for reaching full feeds with placebo was 6 days with interquartile range 3–4 days, for high dose 
was 4 (3–7) days and for low dose 6 (4.3–7) days (p=0.47). The total duration of erythromycin for placebo, high-dose, and low-
dose group was median days 11 (7–14), 9 (7–13), and 9 (7–14), respectively, with p=0.86. There was no difference in the incidence 
of raised liver enzymes, vomiting, sepsis, and need for intravenous fluids, total parenteral nutrition, and duration of hospital stay 
between the groups. None of the babies had adverse events such as fatal arrhythmias and pyloric stenosis. Conclusion: There 
was no significant difference in the time to reach full feeds after erythromycin and the duration of study medication between the 
high-dose and low-dose erythromycin with the placebo group. No adverse effects were seen in any of the groups.
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MATERIALS AND METHODS
This was a double-blind, randomized and placebo-controlled trial 
conducted at a Level III NICU. The duration of the study was 
from January 2009 to June 2010. Institutional ethics committee 
clearance was taken before starting the study. Neonates (term/
preterm) admitted to NICU, having feeding intolerance based 
on the following inclusion criteria: (1) A neonate having any one 
of the following for a 24 h period; gastric residuals more than 
50% of previous feed on one occasion or >30% of previous 
feed on more than three occasions or >10% of total daily feed 
volume [1,14] and (2) the presence of abdominal distension or 
blood in the stools in the absence of sepsis. Babies with major 
congenital anomalies, anatomic gastrointestinal abnormalities, 
and stage 2 or above NEC, treatment with medications such as 
fentanyl/indomethacin/pancuronium or vecuronium at the onset 
of feeding intolerance and sepsis, were excluded from the study.
Eligible babies were included after parental consent. Study 
neonates were screened for the maternal risk factors, which 
predispose to small for gestational age (SGA) and compromised 
gut - abruptio placenta, oligohydramnios, non-reactive stress test, 
and uteroplacental/fetoplacental insufficiency, as diagnosed by 
Doppler. Fetal and neonatal risk factors were recorded. They were 
hypoxia, respiratory distress syndrome or pneumonia requiring 
ventilation, patent ductus arteriosus, perinatal asphyxia, apnea, 
polycythemia, shock, aminophylline use, and magnesium toxicity.
Computer-generated randomization in blocks of six was done. 
The subjects were randomized into Groups 1, 2, and 3, to receive 
low-dose (3 mg/kg/dose) and high-dose (10 mg/kg/dose) oral 
erythromycin or placebo (5% dextrose) medication given 8th h. The 
coding was done by a person who was not involved in the patient 
care, and the allocation concealment was achieved by keeping 
in serially numbered opaque sealed envelopes. Investigators and 
patient care team were blinded for the treatment allocation. The 
study medication erythromycin estolate of concentration (Syrup 
Eltocin, 125 mg/5 ml was used as available in the pharmacy) was 
prepared to the final volume of 1 ml in a glass syringe and covered 
with aluminum foil, to mask the pink color of medication, which 
was administered by orogastric route. The feeding volume and 
progression of feeds were as per NICU feeding protocol for all 
the groups (Table 1).
Expressed breast milk was used and if milk was not available, 
then 5% dextrose was used to make up the volume till mother 
expresses the adequate milk volume, as our unit had a protocol of 
not using the formula feeds. The enteral feeds were adjusted for 
both term and preterm babies according to the gastric residuals:
If the residual was >50% volume per feed - discarded, one 
feed skipped, blood sugars were monitored. If >50% with altered 
aspirates with other symptoms - started on intravenous fluids and 
the baby was kept nil by mouth for 6 h. Feeding was stopped 
when there was feed intolerance and restarted as soon as the 
above signs and symptoms subside. When the babies were kept 
nil per oral, study medicine was continued. Babies who persisted 
to have feed intolerance even after 48 h of study medication, the 
conventional prokinetic, oral domperidone at 0.3 mg/kg/dose was 
given. Those babies continued to have feed intolerance, even after 
domperidone, were started on infusions feeds and the need for 
continuous infusions was documented.
Study medication was given for 7 days after they reach full 
feeds or for a period of total 14 days or the day of discharge 
whichever is earlier. Babies were examined at least twice a 
day and were closely monitored for vomiting, gastric residuals, 
abdominal girth, and gastric aspirates every prefeeds. To monitor 
for the safety, the babies were monitored by a pulse oximeter, 
to look for variations in the heart rate and a cardiac monitor if 
needed. Bilirubin assessment (total and conjugated fraction) 
or aspartate aminotransferase (AST)/alanine aminotransferase 
(ALT)/alkaline phosphatase (ALP) was done at baseline and after 
7 days of erythromycin. Before inclusion, septic workup was 
done to rule out sepsis in babies who had feed intolerance, and 
as required based on symptoms. Ultrasound examination was 
planned if the baby had persistent vomiting >2 times/day, to look 
for the complications like pyloric stenosis.
Primary Outcome
Time to reach full feeds of 150ml/kg, without having significant 
gastric residuals.
Secondary Outcome
Occurrence of sepsis, NEC, adverse effects (hypertrophic pyloric 
stenosis, arrhythmias), need of domperidone, infusion feeds, 
abnormality of liver enzymes, vomiting, and duration of hospital 
stay.
Babies were considered to have sepsis when they had clinical 
picture with the presence of any two of the following - complete 
blood count or C-reactive protein or positive blood culture. If 
the septic parameters were negative, babies were included in 
the study. If the isolate was coagulate negative Staphylococcus, 
they were included when repeat blood culture was negative. 
NEC was confirmed by clinical, biochemical, and radiographic 
methods [21]. Cholestasis was diagnosed when conjugated 
bilirubin is >15% of the total, AST, ALT, or ALP more than the 
reference values for that age [22].
Sample Size
Sample size was calculated based on the previous study [23]. 
Mean time taken to reach full feeds was taken as 5 days for 
treatment group and 10 days for control groups, with standard 
deviation (SD) 1, with 5% of level and 80% power. Sample size 
required was 35 in each group.
All analyses were done using SPSS software. Descriptive data 
were reported as mean ± SD, median with interquartile range 
(IQR), and number with percentages. Categorical data were 
analyzed using Chi-square/Fisher’s exact test. Kruskal–Wallis 
test was done to compare the median of three arms. ANCOVA 
was done to compare the time for reaching full feeds between 
the study groups, for aminophylline as a variable. Results were 
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considered statistically significant if p<0.05. All the analyses 
were done with SPSS version 21.0.
RESULTS
The total number of babies admitted to NICU during the study 
period was 1653. Of which 97 babies had feed intolerance and 
60 babies eligible for the study, were randomized. Flow diagram 
of the recruitment is shown in Fig. 1. Two babies were excluded 
from the study as they were on fentanyl and domperidone at the 
time of randomization. A total number of babies in placebo, high, 
and low dose EM were 19, 19, and 20, respectively.
Demographic characteristics of the babies were similar 
between the three groups as shown in Table 2. Total babies who 
were exposed to maternal risk factors and neonatal risk factors 
for feed intolerance in the study group were 46 (79.3%) and 
49 (84.4%) (Table 3).
Of 58 babies, 40 (68.9%) babies received first feeds as 
breast milk and 18 (31%) babies were fed initially with 5% 
dextrose fluids, 49 (84.4%) babies had received bolus feeds 
and 9 (15.5%) babies received infusion feeds during the study 
period. There were 9 (15.5%) babies on aminophylline. The 
median age at start of feeds was day 2 with interquartile range 
of 1–2, 1–4, and 1–3 days in placebo, high-dose, and low-dose 
groups, respectively. The postnatal day of reaching full feeds 
was the median day 11 (8–15), 14 (10, 22), and 11 (9.25–17.8), 
respectively (p=0.50) and time to reach full feeds after 
medication was median day 6 (3–9), 4 (3–7), and 6 (4.3–7) 
in placebo, high, and low-dose groups, respectively (p=0.47). 
The duration of study medication with the placebo, high, and 
low-dose group was the median of 11 (7–14), 9 (7–13), and 
9 (7–14) days, respectively (p=0.86). One baby died in placebo 
Figure 1: Study flowchart 
Table 3: Primary outcome: Feeding detail between the groups
Variables median (25th, 75th) Placebo High dose Low dose p value
Postnatal day for reaching full feeds 11.0 (8, 15) 14.0 (10, 22) 11 (9.25, 17.8) 0.509
Day for full feeds after study medicine 6.0 (3, 9) 4.0 (3, 7) 6.0 (4.3, 7) 0.477
Total duration of study drug in days 11.0 (7, 14) 9.0 (7, 13) 9.0 (7, 14) 0.869
Table 2: Demographic details between the groups
Variables Placebo (n=19) High dose (n=19) Low dose (n=20) p value
Mean gestation 33.21 (2.2) 33.16 (3.65) 33.6 (3.218) 0.705
Mean birth weight 1616±553 1621±724 1663±556
AGA:SGA 9:10 13:6 15:5 0.175
Male:female 11:8 10:9 12:8 0.893
Preterm:term 18:1 14:5 17:3 0.200
Maternal risk factor 16 (84.2) 13 (68.4) 17 (85) 0.35
Postnatal risk factor 15 (78.9) 17 (89.4) 17 (85) 0.66
Received antenatal steroids (n=43) 14 (87.5) 10 (71.4) 13 (100) 0.09
Aminophylline use 4 (23.5) 3 (16.7) 2 (10.0) 0.540
Age at enrollment median (25th, 75th) 6.0 (3–10) 8.0 (5–14) 5.5 (4–8.8) 0.144
SGA: Small for gestational age, AGA- Appropriate for gestational age
Table 1: Increment of feeds
VLBW babies without risk factors for NEC Sick VLBW babies with risk factors for NEC Sick term babies
Oral feeds - 20 ml/kg/day when 
hemodynamically stable and increased at 
20–35 ml/kg/day as bolus as per the tolerance
Hemodynamically stable babies: Feeds started 
as trophic feeds, at 10 ml/kg/day, divided into 
4–6 times/day and increased in increments of not 
more than 20 ml/kg/day
Intravenous fluids - 60 ml/kg and feed 
was started when hemodynamically 
stable at 20–30 ml/kg/d
VLBW: Very low birth weight, NEC: Necrotizing enterocolitis
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group. No mortality was noted in high-dose and low-dose 
group (Table 4).
DISCUSSION
Feed intolerance is a major problem in neonates; especially, in 
preterm infants admitted to NICU. Erythromycin, an antibiotic 
which is also a prokinetic, has been used to promote feed tolerance. 
Erythromycin exerts its gastrointestinal motor effects through 
activation of motilin receptors on cholinergic nerves, which are 
stimulated by low dose (1–3 mg/kg/dose) and augment Phase III 
MMC and smooth muscle motilin receptor of upper gastrointestinal 
tract [24], which can be stimulated by high dose (10 mg/kg/dose) 
and produce sustained antral contractions, promoting antroduodenal 
coordination [4,25-27]. The combinations of these actions are likely 
to produce propulsive forces, which effectively propel the gastric 
luminal contents distantly toward small and large bowel.
There are many randomized controlled trials since decades, 
which have studied the prokinetic effect of erythromycin at different 
doses, routes, and modes comparing with the placebo. Till now, 
there are no conclusions and recommendations drawn from these 
as the results are inconsistent and contradictory [10,22,28,29]. 
Studies have shown the adverse effects and emergence of 
multidrug resistance microflora in GIT at early age with high dose.
The present study was an RCT to compare the effect of high 
dose and low dose of erythromycin with the placebo in both term 
and preterm infants with feed intolerance. We have included babies 
with gestation of <32 and >32 weeks even though some studies 
which have concluded feed intolerance occur only in babies with 
gestation >32 weeks [6,30]. There are studies concluding feed 
intolerance has been seen in preterms with both <32 weeks [6,30] 
and >32 weeks gestation [25,31].
Erythromycin estolate oral preparation was used in our 
study, in view of concerns about side effects of arrhythmias with 
intravenous preparation [32]. Erythromycin ethyl succinate, 
which other studies used [11,12,32-34], was not available. There 
were no differences in the baseline characteristics, maternal 
and neonatal risk factors such as gestational age, birth weight, 
perinatal asphyxia, and severity of initial pulmonary diseases 
between the groups in our study. There were more male babies 
and higher mean gestation and mean birth weight in our study 
than others. The placebo group had more preterm and SGA babies 
as compared to other groups, which can influence the outcome.
Many RCTs have used EM as a rescue treatment in the recent 
past. Some authors have used low dose - 3–15 mg/kg/d [10-12,33] 
and high dose - 50 mg/kg/d, [12,22,29] and found that erythromycin 
was effective at high doses. In the present study, most of the babies 
were fed with human milk and most feeds were given as bolus. 
There were no differences between the three groups regarding the 
age at starting the feeds and age at enrollment. As compared to 
the studies [23,34,35], time to reach full feeds in our study was 
similar to Ng et al. pilot study. Babies, who received high dose, 
required less time to reach full feeds after study medication, and 
lesser duration of medication as compared to the placebo and 
low-dose group; however, it did not reach statistically significant.
In the high-dose group, the median postnatal day for reaching 
full feeds was 14 (IQR - 10, 22) days, which was longer in this 
group, the reason could be the medication was started at a later age 
than in the other groups. In the low-dose group, age of enrollment 
was earlier than the other groups. The median postnatal day of 
reaching full feeds was 11 (IQR −9.25, 17.75) days and mean was 
15.2±10.4 days and time to reach full feeds after study medication 
was median of 6 (IQR - 4.25, 7) days which was similar to the 
placebo in all the variables except the duration of study medicine 
which was less and is not significant statistically. Similarly, 
many other studies also showed no benefit. Hennawy et al. [10] 
showed that the mean postnatal day of reaching full feeds was 
31±15 days; Ng et al. showed it 24±2.95 days [11] and Cairns 
et al. showed 13.0±14.1 days in their study [12]. Aly et al. have 
shown a positive effect with erythromycin at 1 mg/kg Q8H in 
babies both >32 weeks and <32 weeks gestation and have also 
shown shorter days of TPN requirement [33]. Nagomi et al. have 
used low-dose IV preparation and found it useful; however, it was 
not a prospectively RCT [31].
We also studied the requirement of IV fluids, domperidone, 
and glycerine syringing for irregular stools and side effects such 
as vomiting, cholestasis, sepsis, NEC, and adverse events such as 
hypertrophic infantile pyloric stenosis and arrhythmias and weight 
gain and duration of hospital stay. Requirement of domperidone and 
infusion were less in high-dose group (p>0.05). An abnormal liver 
enzyme level was not significantly different between the groups. 
The duration of hospital stay and weight gain was not significant 
Table 4: Secondary outcomes
Outcomes Placebo n=19 (%) High dose n=19 (%) Low dose n=20 (%) p value
Requirement of domperidone 6 (31.6) 2 (10.5) 6 (30.0) 0.24
Requirement of infusion 4 (21.1) 2 (10.5) 3 (15.0) 0.66
Side effects
Sepsis (n=10) 5 (26.3) 3 (15.8) 2 (10) 0.39
Abnormal LFT (n=5) 1 (7) 2 (15) 2 (14) 0.81
Arrhythmias (clinical) 0 0 0
NEC 1 (5.3) 0 0 0.35
Pyloric stenosis 0 0 0
Duration of hospital stay (days) 16 (12–23) 27 (11–32) 15.5 (11.25–27) 0.36
Weight gain during study median (g) 3.58 (−47.5–22) 3.33 (−25–25.7) 4.22 (−250–25) 0.90
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between the groups. Time to reach full feeds for those who received 
methylxanthine was prolonged as compared to those who did not 
receive methylxanthine (p=0.003). No adverse effects were seen 
in the erythromycin group, and there was no significant difference 
in any of the secondary outcomes between the three study groups.
None of the babies developed adverse effects such as 
arrhythmias or hypertrophic pyloric stenosis. In the placebo 
group, one baby developed NEC Stage III, and died in the course 
of the illness, which had been excluded earlier after the diagnosis 
of NEC-II. Many babies in the placebo group had sepsis, but the 
number was statistically insignificant as compared to other two 
groups. Prolonged liver enzymes seen in the study babies could 
be because of antibiotics or sepsis or related to medication itself, 
but it resolved spontaneously in all these babies.
Ng et al. showed that the number of withheld feeds, duration of 
parenteral nutrition, cholestasis, and incidence of sepsis was less 
in the erythromycin group and increased incidence of parenteral 
nutrition-associated cholestasis in the placebo group [34]. Aly 
et al., who used low-dose erythromycin, reported decrease in 
TPN days [33], but Ng et al. and Nuntnarumit et al. did not show 
any difference in their studies [11,23]. TPN-related cholestasis 
reported by Aly et al. [33] was 13% and sepsis was 13% in the 
erythromycin group (p=1.0). Ng et al. [34] reported one case of 
NEC in the placebo group, and Nuntnarumit et al. [23] reported 
one baby with NEC in erythromycin group and three babies in 
the placebo group. None of the other studies have reported the 
same. Ng et al. [34] showed no difference between erythromycin 
and placebo in the QT interval. None of the studies reported that 
incidence of sepsis including a Cochrane meta-analysis showed 
no difference [36].
A Cochrane meta-analysis in 2008 concluded that there is 
insufficient evidence to recommend the use of erythromycin in 
low or high dose of preterm infants with or at risk of feeding 
intolerance and recommends for future research on erythromycin 
as a prokinetic agent [36]. Even though there was no difference 
between the study groups in postnatal day of reaching FF, all 
babies reached full feeds within 2 weeks of life, which is quite 
acceptable in preterm infants. The fact that the placebo group 
also reached the full feeds within the acceptable time may be the 
babies who were recruited had mild-to-moderate feed intolerance. 
Even though placebo group had more number of preterm, small 
for gestation babies, and high-dose group has more number of 
term babies, there was no statistical difference in time for reaching 
full feeds. Babies with high-dose erythromycin required less time 
to reach full feeds and lesser duration of study medication as 
compared to the placebo and low-dose group; however, it did not 
reach statistically significant. To show the positive effect of high-
dose erythromycin and difference in variables between the study 
groups, we need to meet the required sample size, which could be 
the limitation of the study.
CONCLUSION
There was no significant difference in the time to reach full feeds 
and the duration of study medication between the high-dose and 
low-dose erythromycin and the placebo group. There was no 
significant difference in any of the secondary outcomes between 
the three study groups.
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